Возможности нитрендипина в лечении артериальной гипертензии, профилактике инсульта и когнитивных нарушений в разных клинических ситуациях на амбулаторно-поликлиническом этапе

1. Чазова И.Е., Жернакова Ю.В. Блокаторы кальциевых каналов: более 50 лет на страже здоровья. Системные гипертензии. 2015; 12 (2): 49–56. / Chazova I.E., Zhernakova Iu.V. Blokatory kal'tsievykh kanalov: bolee 50 let na strazhe zdorov'ia. Sistemnye gipertenzii. 2015; 12 (2): 49–56. [in Russian]
2. Задионченко В.С., Шехян Г.Г., Ялымов А.А. и др. Применение блокаторов кальциевых каналов у пациентов с сердечно-сосудистой патологией: фокус на дилтиазем. Consilium Medicum. 2015; 17 (5): 54–62. / Zadionchenko V.S., Shehyan G.G., Yalymov A.A. et al. The application of calcium channel blockers in patients with cardiovascular disease: focus on the diltiazem. Consilium Medicum. 2015; 17 (5): 54–62. [in Russian]
3. Toyo-Oka T, Nayler WG. Third generation calcium entry blockers. Blood Press 1996; 4: 206–8.
4. Остроумова О.Д., Гусева Т.Ф. Антагонисты кальция: современные аспекты применения в кардиологии. Справочник поликлинического врача. 2008; 3: 20–3. / Ostroumova O.D., Guseva T.F. Antagonisty kal'tsiia: sovremennye aspekty primeneniia v kardiologii. Handbook for Practitioners Doctors. 2008; 3: 20–3. [in Russian]
5. van Zwieten PA, Mancia G. Third generation calcium antagonists: further developments. Blood Press 1996; 6: 376–7.
6. Purcell H. Third generation calcium antagonists. Blood Press 1996; 5: 319.
7. Трухан Д.И., Трухан Л.Ю. Пародонтит и сердечно-сосудистые заболевания: параллельно или в одной связке? Consilium Medicum. 2015; 17 (5): 73–9. / Trukhan D.I., Trukhan L.Yu. Periodontal and cardiovascular diseases: In parallel or in a bundle? Consilium Medicum. 2015; 17 (5): 73–79. [in Russian]
8. Трухан Д.И., Трухан Л.Ю. Некоторые аспекты коморбидности пародонтита и сердечно-сосудистых заболеваний. Мед. совет. 2015; 17: 12–6. / Trukhan D.I., Trukhan L.Iu. Nekotorye aspekty komorbidnosti parodontita i serdechno-sosudistykh zabolevanii. Med. sovet. 2015; 17: 12–6. [in Russian]
9. Uneyama H, Takahara A, Wakamori M et al. Pharmacology of N-type Ca2+ channels distributed in cardiovascular system (Review). Int J Mol Med 1999; 5: 455–66.
10. Narita S, Yoshioka Y, I de A et al. Effects of the L/N-type calcium channel antagonist cilnidipine on morning blood pressure control and peripheral edema formation. J Am Soc Hypertens 2011; 5: 410–6.
11. Adake P, Somashekar HS, Mohammed Rafeeq PK et al. Comparison of amlodipine with cilnidipine on antihypertensive efficacy and incidence of pedal edema in mild to moderate hypertensive individuals: A prospective study. J Adv Pharm Technol Res 2015; 6: 81–5.
12. Трухан Д.И., Сайфутдинов Р.Г. Цилнидипин (CILNIDIPINE) – блокатор кальциевых каналов L- и N-типа. Дневник Казанской медицинской школы. 2016; 2: 60–5. / Trukhan D.I., Saifutdinov R.G. Tsilnidipin (CILNIDIPINE) – blokator kal'tsievykh kanalov L- i N-tipa. Dnevnik Kazanskoi meditsinskoi shkoly. 2016; 2: 60–5. [in Russian]
13. Трухан Д.И. Цилнидипин (Cilnidipine) – дигидропиридиновый блокатор кальциевых каналов 4-го поколения. Междунар. журн. прикладных и фундаментальных исследований. 2016; 4–6: 1109–14. / Trukhan D.I. Tsilnidipin (Cilnidipine) – digidropiridinovyi blokator kal'tsievykh kanalov 4-go pokoleniia. Mezhdunar. zhurn. prikladnykh i fundamental'nykh issledovanii. 2016; 4–6: 1109–14 [in Russian]
14. Nitrendipine (Нитрендипин). URL: https://www.vidal.ru/drugs/molecule/749 / Nitrendipine (Nitrendipin). URL: https://www.vidal.ru/drugs/molecule/749 [in Russian]
15. Staessen JA, Fagard R, Thijs L et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997; 350 (9080): 757–64.
16. Forette F, Seux ML, Staessen JA et al. Systolic Hypertension in Europe Investigators. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med 2002; 162 (18): 2046–52.
17. Tuomilehto J, Rastenyte D, Birkenhager WH et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension: Systolic Hypertension in Europe Trial Investigators. N Engl J Med 1999; 340: 677–84.
18. Клинические рекомендации. Артериальная гипертония у взрослых. Российское медицинское общество по артериальной гипертонии. 2016. URL: http://cr.rosminzdrav.ru/schema.html?id=687#/text / Klinicheskie rekomendatsii. Arterial'naia gipertoniia u vzroslykh. Rossiiskoe meditsinskoe obshchestvo po arterial'noi gipertonii. 2016. URL: http://cr.rosminzdrav.ru/schema.html?id=687#/text [in Russian]
19. Wang JG, Staessen JA, Gong L, Liu L. Chinese trial on isolated systolic hypertension in the elderly. Systolic Hypertension in China (Syst-China) Collaborative Group. Arch Intern Med 2000; 160 (2): 211–20.
20. Bufalino VJ, Masoudi FA, Stranne SK et al. The American Heart Association's recommendations for expanding the applications of existing and future clinical registries: a policy statement from the American Heart Association. Circulation 2011; 123 (19): 2167–79.
21. Чурсина Т.Я., Михалев К.А. «Фармакологический лабиринт», или поиски оптимальной комбинации. Артериальная гипертензия. 2012; 5: 32–8. / Chursina T.Ia., Mikhalev K.A. «Farmakologicheskii labirint», ili poiski optimal'noi kombinatsii. Arterial'naia gipertenziia. 2012; 5: 32–8. [in Russian]
22. Корж А.Н., Говбах И.А. Рациональная комбинированная терапия артериальной гипертензии: оптимизация профилактики цереброваскулярных нарушений. Артериальная гипертензия. 2013; 5: 9–15. / Korzh A.N., Govbakh I.A. Ratsional'naia kombinirovannaia terapiia arterial'noi gipertenzii: optimizatsiia profilaktiki tserebrovaskuliarnykh narushenii. Arterial'naia gipertenziia. 2013; 5: 9–15. [in Russian]
23. Крючкова О.Н., Ицкова Е.А., Лутай Ю.А., Турна Э.Ю. Новые горизонты фиксированной антигипертензивной терапии. Крымский терапевтический журн. 2015; 2: 41–8. / Kriuchkova O.N., Itskova E.A., Lutai Iu.A., Turna E.Iu. Novye gorizonty fiksirovannoi antigipertenzivnoi terapii. Krymskii terapevticheskii zhurn. 2015; 2: 41–8. [in Russian]
24. Forette F, Seux ML, Staessen JA. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe trial. Lancet 1998; 352: 1347–51.
25. Энанорм (Enanorm). Инструкция по применению, противопоказания, состав и цена. URL:http://www.rlsnet.ru/tn_index_id_49497.htm / Enanorm (Enanorm). Instruktsiia po primeneniiu, protivopokazaniia, sostav i tsena. URL: http://www.rlsnet.ru/tn_index_id_49497.htm [in Russian]
26. Трухан Д.И., Поздняков Ю.М. Актуальные аспекты рациональной фармакотерапии в кардиологии. Плюсы и минусы фиксированных и произвольных комбинаций антигипертензивных препаратов. Consilium Medicum. 2016; 18 (1): 25–31. / Trukhan D.I., Pozdnyakov Yu.M. Actual aspects of rational pharmacotherapy in cardiology. Pros and cons fixed and arbitrary combinations of antihypertensive drugs. Consilium Medicum. 2016; 18 (1): 25–31. [in Russian]
27. Трухан Д.И., Поздняков Ю.М. Лечение артериальной гипертензии проблемы реальной клинической практики. Справочник поликлинического врача. 2016; 3: 4–8. / Trukhan D.I., Pozdniakov Iu.M. Lechenie arterialnoi gipertenzii problemy realnoi klinicheskoi praktiki. Handbook for Practitioners Doctors. 2016; 3: 4–8. [in Russian]
28. Трухан Д.И., Мазуров А.Л. Легкие и умеренные когнитивные нарушения: актуальные вопросы диагностики и лечения на этапе оказания первичной медико-санитарной помощи. Consilium Medicum. 2016; 18 (2): 74–80. / Trukhan D.I., Mazurov A.L. Mild to moderate cognitive impairment: current issues of diagnosis and treatment in primary health care. Consilium Medicum. 2016; 18 (2): 74–80. [in Russian]
29. Трухан Д.И., Давыдов Е.Л. Профилактика инсульта, когнитивных нарушений и деменции у пациентов с артериальной гипертензией на этапе оказания первичной медико-санитарной помощи. Consilium Medicum. 2017; 19 (1): 50–5. / Trukhan D.I., Davydov E.L. Prevention of stroke, cognitive impairment and dementia in patients with hypertension during the provision of primary health care. Consilium Medicum. 2017; 19 (1): 50–55. [in Russian]
30. Захаров В.В., Яхно Н.Н. Когнитивные расстройства в пожилом и старческом возрасте: Методическое пособие для врачей. М., 2005. / Zakharov V.V., Iakhno N.N. Kognitivnye rasstroistva v pozhilom i starcheskom vozraste: Metodicheskoe posobie dlia vrachei. M., 2005. [in Russian]
31. PROGRESS Collaborative Group. Randomised trial of perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033–41.
32. Преображенская И.С., Науменко А.А. Патогенез, диагностика и терапия болезни Альцгеймера. Мед. совет. 2015; 5: 46–54. / Preobrazhenskaia I.S., Naumenko A.A. Patogenez, diagnostika i terapiia bolezni Al'tsgeimera. Med. sovet. 2015; 5: 46–54. [in Russian]
33. Котов А.С., Елисеев Ю.В., Семенова Е.И. Болезнь Альцгеймера: от теории к практике. Мед. совет. 2015; 18: 41–4. / Kotov A.S., Eliseev Iu.V., Semenova E.I. Bolezn' Al'tsgeimera: ot teorii k praktike. Med. sovet. 2015; 18: 41–4. [in Russian]
34. Parneti L, Senin U, Mecocci P. Cognitive enhancement therapy for Alzheimer's disease: the way forward. Drugs 1997; 53: 752–68.
35. Mason RP, Leeds PR, Jacob PF et al. Inhibition of excessive neuronal apoptosis by the calcium antagonist amlodipine and antioxidants in cerebellar granule cells. J Neurochem 1999; 72: 1448–56.
36. Thibault O, Porter NM, Chen KC. Calcium Dysregulation in neuronal aging and Alzheimer's disease: hystory and new directions. Cell Calcium 1998; 25: 417–33.
37. Zipfel GJ, Lee JM, Choi DW. Reducing calcium overload in the ischemic brain. N Engl J Med 1999; 341: 1543–4.
38. Poscale A, Etchoberrigaray R. Calcium alterations in Alzheimer's disease: pathophysiology, models and therapeutic opportunities. Pharmacol Res 1999; 39: 81–8.
39. Lublin AL, Gandy S. Amyloid-beta oligomers: possible roles as key neurotoxins in Alzheimer’s Disease. Mt Sinai J Med 2010;77:43–9.
40. Hong YL. The relationship between calcium antagonist-induced hypotension and central monoaminergic system in spontaneously hypertensive rats. Int J Clin Pharmacol Ther Toxicol 1987; 11: 589–97.
41. Murzenok PP, Huang BS, Leenen FHH. Sympathoinhibition by central and periferal infusion of nifedipine in spontaneously hypertensive rats. Hypertension 2000; 35: 631–6.
42. Bell RD, Zlokovic BV. Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer’s disease. Acta Neuropathol 2009; 118: 103–13.
43. Deane R, Bell RD, Sagare A, Zlokovic BV. Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer’s disease. CNS Neurol Disord Drug Targets 2009; 8: 16–30.
44. Gould RJ, Murphy KMM, Snyder SH. Autoradiographic localization of calcium channel antagonist receptors in rats brain with [3H] nitrendipine. Brain Res 1985; 330: 217–33.
45. Paris D, Bachmeier C, Patel N et al. Selective antihypertensive dihydropyridines lower Aβ accumulation by targeting both the production and the clearance of Aβ across the blood-brain barrier. Mol Med 2011; 17 (3–4): 149–62.
46. Bachmeier C, Beaulieu-Abdelahad D, Mullan M, Paris D. Selective dihydropyridin compounds facilitate the clearenceof amiloid across the blood-brain barrier. Eur J Pharmacol 2011; 659 (2–3): 124–9.
47. Hanon O, Forette F. Prevention of dementia: lessons from SYST-EUR and PROGRESS. J Neurol Sci 2004; 226: 71–4.
48. Yasar S, Corrada M, Brookmeyer R, Kawas C. Calcium channel blockers and risk of AD: the Baltimore Longitudinal Study of Aging. Neurobiol Aging 2005; 26: 157–63.
49. Duron E, Hanon O. Antihypertensive treatments, cognitive decline, and dementia. J Alzheimers Dis 2010; 20: 903–14.
50. Spinar J, Vitovec J. AII antagonists in the treatment of hypertension and prevention of CVA. Vnitr Lek 2013; 59 (1): 71–8.
51. Coca A. Hypertension and vascular dementia in the elderly: the potential role of anti-hypertensive agents.Curr Med Res Opin 2013; 29 (9): 1045–54.
52. Godfraind T. Calcium channel blockers in cardiovascular pharmacotherapy. J Cardiovasc Pharmacol Ther 2014; 19 (6): 501–15.
53. Peters J, Booth A, Peters R. Potential for specific dihydropyridine calcium channel blockers to have a positive impact on cognitive function in humans: a systematic review. Ther Adv Chronic Dis 2015; 6 (4): 160–9.
54. Трухан Д.И., Викторова И.А. Внутренние болезни: Кардиология. Ревматология. М.: ООО «Медицинское информационное агентство», 2013. / Trukhan D.I., Viktorova I.A. Vnutrennie bolezni: Kardiologiia. Revmatologiia. M.: OOO «Meditsinskoe informatsionnoe agentstvo», 2013. [in Russian]
55. Трухан Д.И. Рациональная фармакотерапия в кардиологии сквозь призму коморбидности и лекарственной безопасности. Справочник поликлинического врача. 2015; 1: 26–31. / Trukhan D.I. Ratsional'naia farmakoterapiia v kardiologii skvoz' prizmu komorbidnosti i lekarstvennoi bezopasnosti. Handbook for Practitioners Doctors. 2015; 1: 26–31. [in Russian]
56. Ann Twiss M, Harman E, Chesrown S, Hendeles L. Efficacy of calcium channel blockers as main-tenance therapy for asthma. Br J Clin Pharmacol 2002; 53 (3): 243–9.
57. Dart RA, Gollub S, Lazar J et al. Treatment of systemic hypertension in patients with pulmonary disease. Chest 2003; 123 (1): 222–43.
58. Chandy D, Aronow WS, Banach M. Current perspectives on treatment of hypertensive patients with chronic obstructive pulmonary disease. Integr Blood Press Control 2013; 6: 101–9.
59. Кароли Н.А., Ребров А.П. Современные подходы к лечению артериальной гипертензии у больных ХОБЛ (обзор литературы). Consilium Medicum. Болезни органов дыхания (Прил. к журн. Consilium Medicum). 2013; 53–9. / Karoli N.A., Rebrov A.P. Sovremennye podkhody k lecheniiu arterial'noi gipertenzii u bol'nykh KhOBL (obzor literatury). Respiratory Organs Diseases (Suppl. Consilium Medicum). 2017; 2013; 53–9. [in Russian]
60. Herrin MA, Feemster LC, Crothers K et al. Combination antihypertensive therapy among patients with COPD. Chest 2013; 143 (5): 1312–20.
61. Трухан Д.И. Выбор лекарственного препарата с позиций рациональной фармакотерапии. Consilium Medicum. 2013; 11: 45–9. / Trukhan D.I. Vybor lekarstvennogo preparata s pozitsii ratsional'noi farmakoterapii. Consilium Medicum. 2013; 11: 45–9. [in Russian]
62. Трухан Д.И., Поздняков Ю.М. Выбор диуретика для лечения артериальной гипертензии с позиций рациональной фармакотерапии. Справочник поликлинического врача. 2015; 10: 4–9. / Trukhan D.I., Pozdniakov Iu.M. Vybor diuretika dlia lecheniia arterial'noi gipertenzii s pozitsii ratsional'noi farmakoterapii. Handbook for Practitioners Doctors. 2015; 10: 4–9. [in Russian]
63. Montalescot G, Sechtem U, Achenbach S et al. 2013 ESC guidelines on the management of stable coronary artery disease. Eur Heart J 2013; 34 (38): 2949–3003.

________________________________________________

1. Chazova I.E., Zhernakova Iu.V. Blokatory kal'tsievykh kanalov: bolee 50 let na strazhe zdorov'ia. Sistemnye gipertenzii. 2015; 12 (2): 49–56. [in Russian]
2. Zadionchenko V.S., Shehyan G.G., Yalymov A.A. et al. The application of calcium channel blockers in patients with cardiovascular disease: focus on the diltiazem. Consilium Medicum. 2015; 17 (5): 54–62. [in Russian]
3. Toyo-Oka T, Nayler WG. Third generation calcium entry blockers. Blood Press 1996; 4: 206–8.
4. Ostroumova O.D., Guseva T.F. Antagonisty kal'tsiia: sovremennye aspekty primeneniia v kardiologii. Handbook for Practitioners Doctors. 2008; 3: 20–3. [in Russian]
5. van Zwieten PA, Mancia G. Third generation calcium antagonists: further developments. Blood Press 1996; 6: 376–7.
6. Purcell H. Third generation calcium antagonists. Blood Press 1996; 5: 319.
7. Trukhan D.I., Trukhan L.Yu. Periodontal and cardiovascular diseases: In parallel or in a bundle? Consilium Medicum. 2015; 17 (5): 73–79. [in Russian]
8. Trukhan D.I., Trukhan L.Iu. Nekotorye aspekty komorbidnosti parodontita i serdechno-sosudistykh zabolevanii. Med. sovet. 2015; 17: 12–6. [in Russian]
9. Uneyama H, Takahara A, Wakamori M et al. Pharmacology of N-type Ca2+ channels distributed in cardiovascular system (Review). Int J Mol Med 1999; 5: 455–66.
10. Narita S, Yoshioka Y, I de A et al. Effects of the L/N-type calcium channel antagonist cilnidipine on morning blood pressure control and peripheral edema formation. J Am Soc Hypertens 2011; 5: 410–6.
11. Adake P, Somashekar HS, Mohammed Rafeeq PK et al. Comparison of amlodipine with cilnidipine on antihypertensive efficacy and incidence of pedal edema in mild to moderate hypertensive individuals: A prospective study. J Adv Pharm Technol Res 2015; 6: 81–5.
12. Trukhan D.I., Saifutdinov R.G. Tsilnidipin (CILNIDIPINE) – blokator kal'tsievykh kanalov L- i N-tipa. Dnevnik Kazanskoi meditsinskoi shkoly. 2016; 2: 60–5. [in Russian]
13. Trukhan D.I. Tsilnidipin (Cilnidipine) – digidropiridinovyi blokator kal'tsievykh kanalov 4-go pokoleniia. Mezhdunar. zhurn. prikladnykh i fundamental'nykh issledovanii. 2016; 4–6: 1109–14 [in Russian]
14. Nitrendipine (Nitrendipin). URL: https://www.vidal.ru/drugs/molecule/749 [in Russian]
15. Staessen JA, Fagard R, Thijs L et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997; 350 (9080): 757–64.
16. Forette F, Seux ML, Staessen JA et al. Systolic Hypertension in Europe Investigators. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med 2002; 162 (18): 2046–52.
17. Tuomilehto J, Rastenyte D, Birkenhager WH et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension: Systolic Hypertension in Europe Trial Investigators. N Engl J Med 1999; 340: 677–84.
18. Klinicheskie rekomendatsii. Arterial'naia gipertoniia u vzroslykh. Rossiiskoe meditsinskoe obshchestvo po arterial'noi gipertonii. 2016. URL: http://cr.rosminzdrav.ru/schema.html?id=687#/text [in Russian]
19. Wang JG, Staessen JA, Gong L, Liu L. Chinese trial on isolated systolic hypertension in the elderly. Systolic Hypertension in China (Syst-China) Collaborative Group. Arch Intern Med 2000; 160 (2): 211–20.
20. Bufalino VJ, Masoudi FA, Stranne SK et al. The American Heart Association's recommendations for expanding the applications of existing and future clinical registries: a policy statement from the American Heart Association. Circulation 2011; 123 (19): 2167–79.
21. Chursina T.Ia., Mikhalev K.A. «Farmakologicheskii labirint», ili poiski optimal'noi kombinatsii. Arterial'naia gipertenziia. 2012; 5: 32–8. [in Russian]
22. Korzh A.N., Govbakh I.A. Ratsional'naia kombinirovannaia terapiia arterial'noi gipertenzii: optimizatsiia profilaktiki tserebrovaskuliarnykh narushenii. Arterial'naia gipertenziia. 2013; 5: 9–15. [in Russian]
23. Kriuchkova O.N., Itskova E.A., Lutai Iu.A., Turna E.Iu. Novye gorizonty fiksirovannoi antigipertenzivnoi terapii. Krymskii terapevticheskii zhurn. 2015; 2: 41–8. [in Russian]
24. Forette F, Seux ML, Staessen JA. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe trial. Lancet 1998; 352: 1347–51.
25. Enanorm (Enanorm). Instruktsiia po primeneniiu, protivopokazaniia, sostav i tsena. URL: http://www.rlsnet.ru/tn_index_id_49497.htm [in Russian]
26. Trukhan D.I., Pozdnyakov Yu.M. Actual aspects of rational pharmacotherapy in cardiology. Pros and cons fixed and arbitrary combinations of antihypertensive drugs. Consilium Medicum. 2016; 18 (1): 25–31. [in Russian]
27. Trukhan D.I., Pozdniakov Iu.M. Lechenie arterialnoi gipertenzii problemy realnoi klinicheskoi praktiki. Handbook for Practitioners Doctors. 2016; 3: 4–8. [in Russian]
28. Trukhan D.I., Mazurov A.L. Mild to moderate cognitive impairment: current issues of diagnosis and treatment in primary health care. Consilium Medicum. 2016; 18 (2): 74–80. [in Russian]
29. Trukhan D.I., Davydov E.L. Prevention of stroke, cognitive impairment and dementia in patients with hypertension during the provision of primary health care. Consilium Medicum. 2017; 19 (1): 50–55. [in Russian]
30. Zakharov V.V., Iakhno N.N. Kognitivnye rasstroistva v pozhilom i starcheskom vozraste: Metodicheskoe posobie dlia vrachei. M., 2005. [in Russian]
31. PROGRESS Collaborative Group. Randomised trial of perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033–41.
32. Preobrazhenskaia I.S., Naumenko A.A. Patogenez, diagnostika i terapiia bolezni Al'tsgeimera. Med. sovet. 2015; 5: 46–54. [in Russian]
33. Kotov A.S., Eliseev Iu.V., Semenova E.I. Bolezn' Al'tsgeimera: ot teorii k praktike. Med. sovet. 2015; 18: 41–4. [in Russian]
34. Parneti L, Senin U, Mecocci P. Cognitive enhancement therapy for Alzheimer's disease: the way forward. Drugs 1997; 53: 752–68.
35. Mason RP, Leeds PR, Jacob PF et al. Inhibition of excessive neuronal apoptosis by the calcium antagonist amlodipine and antioxidants in cerebellar granule cells. J Neurochem 1999; 72: 1448–56.
36. Thibault O, Porter NM, Chen KC. Calcium Dysregulation in neuronal aging and Alzheimer's disease: hystory and new directions. Cell Calcium 1998; 25: 417–33.
37. Zipfel GJ, Lee JM, Choi DW. Reducing calcium overload in the ischemic brain. N Engl J Med 1999; 341: 1543–4.
38. Poscale A, Etchoberrigaray R. Calcium alterations in Alzheimer's disease: pathophysiology, models and therapeutic opportunities. Pharmacol Res 1999; 39: 81–8.
39. Lublin AL, Gandy S. Amyloid-beta oligomers: possible roles as key neurotoxins in Alzheimer’s Disease. Mt Sinai J Med 2010;77:43–9.
40. Hong YL. The relationship between calcium antagonist-induced hypotension and central monoaminergic system in spontaneously hypertensive rats. Int J Clin Pharmacol Ther Toxicol 1987; 11: 589–97.
41. Murzenok PP, Huang BS, Leenen FHH. Sympathoinhibition by central and periferal infusion of nifedipine in spontaneously hypertensive rats. Hypertension 2000; 35: 631–6.
42. Bell RD, Zlokovic BV. Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer’s disease. Acta Neuropathol 2009; 118: 103–13.
43. Deane R, Bell RD, Sagare A, Zlokovic BV. Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer’s disease. CNS Neurol Disord Drug Targets 2009; 8: 16–30.
44. Gould RJ, Murphy KMM, Snyder SH. Autoradiographic localization of calcium channel antagonist receptors in rats brain with [3H] nitrendipine. Brain Res 1985; 330: 217–33.
45. Paris D, Bachmeier C, Patel N et al. Selective antihypertensive dihydropyridines lower Aβ accumulation by targeting both the production and the clearance of Aβ across the blood-brain barrier. Mol Med 2011; 17 (3–4): 149–62.
46. Bachmeier C, Beaulieu-Abdelahad D, Mullan M, Paris D. Selective dihydropyridin compounds facilitate the clearenceof amiloid across the blood-brain barrier. Eur J Pharmacol 2011; 659 (2–3): 124–9.
47. Hanon O, Forette F. Prevention of dementia: lessons from SYST-EUR and PROGRESS. J Neurol Sci 2004; 226: 71–4.
48. Yasar S, Corrada M, Brookmeyer R, Kawas C. Calcium channel blockers and risk of AD: the Baltimore Longitudinal Study of Aging. Neurobiol Aging 2005; 26: 157–63.
49. Duron E, Hanon O. Antihypertensive treatments, cognitive decline, and dementia. J Alzheimers Dis 2010; 20: 903–14.
50. Spinar J, Vitovec J. AII antagonists in the treatment of hypertension and prevention of CVA. Vnitr Lek 2013; 59 (1): 71–8.
51. Coca A. Hypertension and vascular dementia in the elderly: the potential role of anti-hypertensive agents.Curr Med Res Opin 2013; 29 (9): 1045–54.
52. Godfraind T. Calcium channel blockers in cardiovascular pharmacotherapy. J Cardiovasc Pharmacol Ther 2014; 19 (6): 501–15.
53. Peters J, Booth A, Peters R. Potential for specific dihydropyridine calcium channel blockers to have a positive impact on cognitive function in humans: a systematic review. Ther Adv Chronic Dis 2015; 6 (4): 160–9.
54. Trukhan D.I., Viktorova I.A. Vnutrennie bolezni: Kardiologiia. Revmatologiia. M.: OOO «Meditsinskoe informatsionnoe agentstvo», 2013. [in Russian]
55. Trukhan D.I. Ratsional'naia farmakoterapiia v kardiologii skvoz' prizmu komorbidnosti i lekarstvennoi bezopasnosti. Handbook for Practitioners Doctors. 2015; 1: 26–31. [in Russian]
56. Ann Twiss M, Harman E, Chesrown S, Hendeles L. Efficacy of calcium channel blockers as main-tenance therapy for asthma. Br J Clin Pharmacol 2002; 53 (3): 243–9.
57. Dart RA, Gollub S, Lazar J et al. Treatment of systemic hypertension in patients with pulmonary disease. Chest 2003; 123 (1): 222–43.
58. Chandy D, Aronow WS, Banach M. Current perspectives on treatment of hypertensive patients with chronic obstructive pulmonary disease. Integr Blood Press Control 2013; 6: 101–9.
59. Karoli N.A., Rebrov A.P. Sovremennye podkhody k lecheniiu arterial'noi gipertenzii u bol'nykh KhOBL (obzor literatury). Respiratory Organs Diseases (Suppl. Consilium Medicum). 2017; 2013; 53–9. [in Russian]
60. Herrin MA, Feemster LC, Crothers K et al. Combination antihypertensive therapy among patients with COPD. Chest 2013; 143 (5): 1312–20.
61. Trukhan D.I. Vybor lekarstvennogo preparata s pozitsii ratsional'noi farmakoterapii. Consilium Medicum. 2013; 11: 45–9. [in Russian]
62. Trukhan D.I., Pozdniakov Iu.M. Vybor diuretika dlia lecheniia arterial'noi gipertenzii s pozitsii ratsional'noi farmakoterapii. Handbook for Practitioners Doctors. 2015; 10: 4–9. [in Russian]
63. Montalescot G, Sechtem U, Achenbach S et al. 2013 ESC guidelines on the management of stable coronary artery disease. Eur Heart J 2013; 34 (38): 2949–3003.

Д.И.Трухан*1, Ю.М.Поздняков2

1 ФГБОУ ВО «Омский государственный медицинский университет» Минздрава России. 644099, Россия, Омск, ул. Ленина, д. 12;
2 «Московский областной кардиологический центр». 140180, Россия, Московская область, г. Жуковский, ул. Фрунзе, д. 1
*dmitry_trukhan@mail.ru

________________________________________________

D.I.Trukhan*1, Yu.M.Pozdnyakov2

1 Omsk State Medical  University of the Ministry of Health of the Russian Federation. 644099, Russian Federation, Omsk, ul. Lenina, d. 12
2 Moscow Regional Cardiological Center. 140180, Russian Federation, Moscow Region, Zhukovsky, ul. Frunze, d. 1
*dmitry_trukhan@mail.ru